Microdosing ketamine means taking small, spaced oral doses of a prescription anesthetic at home, hoping to lift mood and keep the brain adaptable. In depression, repeated low oral doses reduced symptoms in small controlled studies; the tiniest doses rest mostly on patient reports, and benefit for adults without depression remains largely untested. Harms appear uncommon at small doses, but heavy or unsupervised use risks dependence and bladder damage. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood pressure | Below 120/80 mmHg at rest | Detect ketamine-induced rises |
| Resting heart rate | 50–70 beats per minute | Detect fight-or-flight stimulation |
| ALT (alanine aminotransferase) | Below 25 U/L | Early liver injury |
| GGT (gamma-glutamyl transferase) | Below 25 U/L | Bile-flow (cholestatic) injury |
| Urinalysis (blood, white cells, protein) | Negative for all | Early bladder irritation |
| Creatinine and eGFR (estimated glomerular filtration rate) | eGFR above 90 mL/min/1.73 m² | Upper urinary tract involvement |
| PHQ-9 (Patient Health Questionnaire-9) | Below 5 | Track mood benefit |
| GAD-7 (Generalized Anxiety Disorder-7) | Below 5 | Track anxiety benefit |
| CYP2B6 genotype (optional, once) | No established target; record *1/*1, *1/*6 or *6/*6 | Identify slow metabolizers |
Cadence: Baseline before the first dose; blood pressure before and 60 minutes after each of the first three doses; symptom questionnaires weekly for the first 4 weeks; laboratory tests at 4 weeks, then every 3 months while dosing continues; urinary symptoms at every session